Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360301 · ClinicalTrials.gov registry record · Phase 1
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT07360301: Clinical Trial Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT07360301 is a Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 120 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07360301, a Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.
Primary Outcome
WEMWBS is a 14-item survey scored on a 5 point likert scale. The total range in scores is from 14 to 70 where higher scores indicate better mental wellbeing. Reported here for psilocybin administered while awake to psilocybin administered while asleep.
Interventions
- DRUG Psilocybin
- OTHER Saline Placebo
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What is known before NCT07360301 opens enrollment
NCT07360301 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 3 interventions - of which Psilocybin is the first listed.
NCT07360301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07360301 about?
NCT07360301 is a clinical study titled "Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study". This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from dir...
What is the current status of trial NCT07360301?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2026-09. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07360301?
The interventions under investigation include: Psilocybin (DRUG), Saline Placebo (OTHER), Clonidine (DRUG).
Who is sponsoring clinical trial NCT07360301?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07360301's enrollment target sits among peer trials
120 479th of 2000 higher than 1,503 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia